2848 – Second Generation Antipsychotic-Induced Weight Alteration

Abstract

Introduction:

Atypical antipsychotics are frequently associated with increased risk of weight gain as side effect.

Objective:

To compare body weigh alteration in psychotic disorder patients undergoing atypical neuroleptics therapy.

Methods:

This study included 37 patients with mean age of 35,14 ± 1,57 years old, enrolled in a public mental health service with psychotic disorders related to the use of illicit drugs and schizophrenia.

Results:

Patients treated with atypical neuroleptics such as olanzapine (11) 0,28 mg/kg/day, clozapine (7) 1,56 mg/kg/day and risperidone (10) 0,031 mg/kg/day, were evaluated. Haloperidol (9) 0,072 mg/kg/day, as typical neuroleptics was also studied. Neuroleptics’ treatment period was 126,97 ± 20,93 days and the patients inicial body weight mean was 67,63 ± 2,13 kg.

Increase of body weight of 1,79 ± 0,72 kg was observed for patients receiving haloperidol, compared with olanzapine 10,37 ± 1,74 kg, clozapine 3,6 ± 2,10 kg and risperidone 1,21 ± 0,90 kg in the end of evaluation period.

These increase of body weight calculated in g/day were 31,68 ± 1,83 g/day for haloperidol, 99,54 ± 25,55 g/day for olanzapine, 27,44 ± 13,35 g/day for clozapine and 13,11 ± 1,40g/day for risperidone.

Increase of body weight index (BWI) at the end of the period of analysis was 0,66 ± 0,25 for haloperidol, 3,59 ± 0,63 for olanzapine, 1,52 ± 0,90 for clozapine and 0,40 ± 0,35 for risperidone.

These BWI increases identified per day were 0,011 ± 0,0038 for haloperidol, 0,034 ± 0,0085 for olanzapine, 0,011 ± 0,0057 for clozapine and 0,0039 ± 0,0055 for risperidone.

Conclusions:

Although haloperidol, olanzapine, clozapine and risperidone act blocking serotonin receptors conducting to body weight gain, they probably act with different intensity degree of blockage.